• Home
  • About us
  • Log-In
  • Join Us
  • Sitemap
  • Recruit
제품/실험 Q&A
자주묻는질문
자유게시판
실험기법
자료신청
논문자료
클레임 접수
기기 A/S 접수
클레임 진행조회
 제품안내  면역학   Neuroscience  Ion Channel

Ca2+ Channel Blockers Econokit

Ca2+ Channel을 blocking 시키는 compound를 소량 모아 경제적인 kit로 공급합니다.

Alomone labs
제품 문의하기
인쇄하기

    구성품
    Compound Properties Cat No. M.W. Solubility Specific Ca 2+
    Channel
    Blockage
    Activity and
    Recommended
    Effective
    Concentrations
    Recommended References
    ω-Agatoxin IVA Agelenopsis aperta 5 μg (>99%) A-500 5202 Water P-/Q-types; 20 nM-1 μM Mintz.I.M. et al. (1992) Nature 355, 827.
    ω-Agatoxin TK Agelenopsis aperta 5 μg (>99%) A-530 5273 Water P-/Q-types; 20 nM-1 μM Teramoto, T. et al. (1995) Neuroreport 6, 1684.
    (±)-Bay K 8644 1 mg (>99%) B-350 356.3 DMSO Active L-type, voltage-gated Ca2+ channel agonist; 1 μM. Hes, P. et al. (1984) Nature 311, 538. Nowycky, M.C. et al. (1985) PNAS USA 82, 2178.
    Calcicludine Dendroaspis angusticeps 70 μg (>98%) C-650 6979 Water Neuronal L-type; 1-10nM Schweitz, H. et al. (1994) P.N.A.S. USA 91, 878.
    Calciseptine Dendroaspis p. polylepis 70 μg (>98% C-500 7036 Water L-type; 100nM-2μM De Weille, J.R. et al. (1991) P.N.A.S. USA 88, 2437.
    ω-Conotoxin GVIA Conus geographus 0.1 mg (>99%) C-300 3037 Water N-type; 100nM-1μM Olivera, B.M. et al. (1985) Science 230, 1338.
    ω-Conotoxin MVIIA Conus magus 50 μg (>99%) C-670 2639 Water N-type (reversible); 100nM-2μM Olivera, B.M. et al. (1987) Biochemistry 26, 2086.
    ω-Conotoxin MVIIC Conus magus 30 μg (>99%) C-150 2756 Water Q-type, 50nM-1μM Hillyard, D.R. et al. (1992) Neuron 9, 69.
    FS-2 Dendroaspis p. polylepis 70 μg (>98%) F-700 7004 Water L-type; 100nM-2μM. Jean-Pierre, A. et al. (1995) Biochemistry 34, 5923. Wanatabe, T.X. et al. (1995) Jpn. J. Pharmacol. 68, 305.
    ω-Grammotoxin SIA Grammostola spatulata 5 μg (>98%) G-450 4113 Water N-type, P-type; ω-Grammotoxin SIA potently inhibits both CaV2.1 (P-type) and CaV2.2 (N-type) channels by altering the voltage-dependence of channel gating. Lampe R. A., et al.,(1993) Mol.
    Pharmacol. 44, 451.
    Piser T. M., et al.,(1995) Mol.
    Pharmacol. 48, 131.
    McDonough S. I., et al.,(1997) Mol.
    Pharmacol. 52, 1095.
    Nifedipine 100 mg (>98%) 346.34 DMSO L-type; 1-10 μM Triggle, D.J. & Janis, R.A. (1987)
    Annu. Rev. Pharmacol. Toxicol. 27, 34.
    Nimodipine 5 mg (>99%) 418.5 Methanol L-type; 1-2 μM Triggle, D.J. & Janis, R.A. (1987)
    Annu. Rev. Pharmacol. Toxicol. 27, 34
    Pimozide 5 mg (>98%) 461.6 DMSO T-type channel blocker, IC50=40 nM for CaV3.1-3 expressed in HEK cells. In Xenopus oocytes IC50=3 μM for CaV3.1. Santi, C.M. et al. (2002) J. Neurosci. 22, 396.
    PLTX-II Plectreurys tristes 5 μg (>99%) P-510 5109 Water Insect neuronal types, 10-50 nM Leung, H.-T. et al. (1989) Neuron 3, 767.
    SNX-482 Hysterocrates gigas 5 μg (>98%) S-500 4495 Water R-type channel blocker: IC50=15-30 nM. Newcomb, R. et al. (1998) Biochemistry 37,15353.
    Bourniet, E. et al. (2001) Biophys. J. 81, 79.
    Wang, G. et al. (1999) J. Neurosci. 19, 9235.
    TaiCatoxin Oxyuranus s. scutellatus 0.1 mg (>97%) T-800 52,000 Water L-type; 50-500nM Possani, L.D. et al. (1992) Toxicon 30, 1343.

    Compound Properties Cat No. M.W. Solubility Specific Ca 2+
    Channel
    Blockage
    Activity and
    Recommended
    Effective
    Concentrations
    Recommended References
    Amlodipine besylate 10 mg > 99% A-120 567.1 DMSO 1 - 100 μM L-type and
    T-type Ca2+channels
    Burges, R. A. et al. (1987) J. Cardiovasc. Pharmacol. 9,110.
    Julius, S. et al. (2004) The Lancet 363, 2022.
    Furukawa, T. et al. (2005) J. Cardiovasc. Pharmacol. 45, 241.
    Felodipine 5 mg > 99% F-105 384.25 DMSO 1-10 μm L-type
    Ca2+ channels
    Furukawa, T. et al. (1999) J.P.E.T. 291,464.
    Furukawa, T. et al. (2005) J. Cardiovasc. Pharmacol. 45, 241.
    Flunarizine dihydrochloride 1 g > 99% F-110 477.4 DMSO 1 - 200 μM
    L-type Channels
    Todd, P.A. and Benfield, P. (1989) Drugs. 38, 481.
    Tytgat, J. et al. (1988) Naunyn-Schmiedeberg's Arch.Pharmacol. 337, 690.
    Isradipine 5 mg > 99% I-100 371.4 DMSO 50 nM - 5 μM
    L-type Channels
    Ganz, M. et al. (2005) J. Clin. Hypertens. 7, 27.
    Berjukow, S. et al. (2007) J. Biol. Chem. 275, 22114.
    Chan, C.S. et al. (2007) Nature 447, 1081.
    L-651,582 5 mg > 99%. L-110 424.7 DMSO 0.5 - 200 μM L-type Channels 1. Hupe, D.J. et al. (1991) J. Biol. Chem. 266, 10136.
    2. Guo, L. et al. (1991) Eur. J. Pharmacol. 538, 15.
    Nicardipine HCl 1 g > 99% N-125 567.1 DMSO 1 - 100 μM
    L-type and T-type Ca2+ channels
    Ishikawa, T. et al. (1993) Circ. Res. 73, 1128.
    Sorkin, E.M. and Clissold, S. P. (1987) Drugs 33, 296.
    Furukawa, T. et al. (2005) J. Cardiovasc. Pharmacol. 45, 241
    Nifedipine 1 g > 99.8%. N-120 346.3 DMSO 0.1 - 10 μM L-type Cav channels Furukawa, T. et al. (1999) J. Pharmacol. Exp.Ther. 291, 464.
    Sorkin, E.M. et al. (1985) Drugs 30, 182.
    Lundy, A. et al. (2009) Vasc. Health Risk Mang. 5, 429.
    Nimodipine 50 mg > 99% N-150 418.4 DMSO 0.1 - 100 μM
    L-type Cav channels
    Cohen, C.J. and McCarthy, R.T. (1987) J. Physiol. 387, 195.
    McCarthy, R.T. and Cohen, C.J. (1989) J. Gen. Physiol. 94, 669.
    Furukawa, T. et al. (1999) J.Pharmacol. Exp.Ther. 291, 464.
    Furukawa, T. et al. (2005) J. Cardiovasc. Pharmacol. 45, 241.
    PD 173212 5 mg > 99% P-105 599.9 DMSO 10 nM - 10 μM
    N-type Cav channels
    Hu, L.Y. et al. (1999) Bioorg. Med. Chem. Lett. 9, 2151
    Verapamil HCl 1 g > 99% V-100 491.1 DMSO 1 μM - 250 Μm Zanchetti, A. et al. (1998) J. Hypertension 16, 1667.
    Hockerman, G. H. et al. (1997) Annu. Rev. Pharmacol. Toxicol. 37, 361.
    Lacinova, L. et al. (1995) J. Pharmacol. Exp. Ther. 274, 54.
    Huber, I.G. et al. (2004) J. Biol. Chem. 279, 55211.